Myeloproliferative Neoplasms (MPNs) [Excluding CML]

Indolent & Smoldering Systemic Mastocytosis
- HEMPPD0044 Phase II/III BLU-263 in Indolent Systemic Mastocytosis
  PI: Shomali Sponsor: Blueprint Medicines Corporation

Aggressive Systemic Mastocytosis / Mast Cell Leukemia
- CD30-
  - HEMPPD0034 Phase II Avapritinib (BLU-285) KIT Mutation-targeted TKI in Advanced Systemic Mastocytosis
    PI: Gotlib Sponsor: Blueprint Medicines Corp.
    1st Priority
  - HEMPPD0029 Phase I DCC-2618 in Advanced Malignancies
    PI: Gotlib Deciphera Pharmaceuticals
  2nd Priority

- HEMPPD0045 Phase II CGT9486 as a Single Agent in Advanced Systemic Mastocytosis
  PI: Gotlib Sponsor: Cogent Biosciences, Inc.

**KEY**
- Pending
- Open for Enrollment
- Link
- Optional Path
- Extension Study
- Trial Posting
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu